Lexgenleucel-T is in Phase 2 development for HIV treatment.
(Compound details obtained from ChemIDplus Advanced,1 Treatment Action Group website,2 and ClinicalTrials.gov3,4)
What is lexgenleucel-T?
Lexgenleucel-T is an investigationalproduct that is being studied to treat or possibly cure HIV.2-4During therapy, genes are modified in order to treat or prevent disease.
How does lexgenleucel-T work?
Lexgenleucel-T is an investigational gene therapy product that adds an anti-HIV gene (called an antisense gene) into CD4 cells.5
With lexgenleucel-T, the antisense gene is delivered into the CD4 cell by a carrier called a. The antisense gene becomes a permanent part of the cell’s genetic material. Then, when HIV infects a CD4 cell that has the antisense gene and tries to make copies of itself, the antisense gene is activated. The activated antisense gene prevents the production of an HIV (called an protein) that’s needed for HIV to successfully . Without the envelope protein, HIV cannot multiply.5-7
Which clinical trials are studying lexgenleucel-T?
Study Names: NCT00295477
Status: This study has been completed.
Location: United States
Purpose: The purpose of this study was to evaluate the safety and effectiveness of multiple lexgenleucel-T infusions on levels and CD4 counts.8
Study Names: (1) VRX496-USA-05-002; NCT00131560 and (2) VRX496-USA-05-002-Rollover; NCT00622232
Status: These studies are ongoing, but not recruiting participants.
Location: United States
Purpose: The purpose of the VRX496-USA-05-002 study is to evaluate the safety and effectiveness of single and multiple infusions of lexgenleucel-T. The purpose of the rollover study is to evaluate the safety and effectiveness of an additional of lexgenleucel-T in participants who complete the VRX496-USA-05-002 study.3,4
For more details on the studies listed above, see the Health Professional version of this drug summary.
What side effects might lexgenleucel-T cause?
One goal of HIV research is to identify new drugs that have fewer side effects. The following side effects were observed in the studies of lexgenleucel-T listed above.Protocol 802456 (NCT00295477):
No safety concerns related to multiple infusions were reported in this study. The most common side effect was a garlic/creamed corn odor occurring during infusions. Other common side effects related to treatment were reactions at the infusion site, such as stinging and a cold sensation.9,10VRX496-USA-05-002 (NCT00131560) and VRX496-USA-05-002-Rollover (NCT00622232):
Twenty seven participants in these studies have completed 3 years of follow-up safety monitoring with no evidence of long-term safety issues related to lexgenleucel-T treatment.11
Because lexgenleucel-T is still being studied, information on possible side effects of the drug is not complete. As testing of lexgenleucel-T continues, additional information on possible side effects will be gathered.
Where can I get more information about clinical trials studying lexgenleucel-T?
More information about lexgenleucel-T-related research studies is available from ClinicalTrials.gov.
Some clinical trials may be looking for volunteer participants. Your health care provider can help you decide whether participating in a NIH Clinical Research Trials and You.is right for you. For more information, visit
- United States National Library of Medicine. ChemIDplus Advanced: Lexgenleucel-T. https://chem.nlm.nih.gov/chemidplus/rn/1294006-17-9. Accessed December 30, 2019
- Treatment Action Group website. Research toward a cure trials. http://www.treatmentactiongroup.org/cure/trials. Accessed December 30, 2019
- VIRxSYS Corporation. A Phase II, open-label, multicenter study to evaluate the safety, tolerability, and biological activity of single and repeated doses of autologous T cells transduced with VRX496 in HIV-positive subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on August 16, 2005. NLM Identifier: NCT00131560. https://clinicaltrials.gov/ct2/show/NCT00131560. Accessed December 30, 2019
- VIRxSYS Corporation. A rollover study to evaluate safety and therapeutic effect of re-infusing subjects who completed participation in the VRX496-USA-05-002 trial with autologous T cells transduced with VRX496. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 11, 2008. NLM Identifier: NCT00622232. https://clinicaltrials.gov/ct2/show/NCT00622232. AccessedDecember 30, 2019
- VIRxSYS Corporation. FDA biological response modifiers advisory committee meeting briefing package—Autologous T cells transduced with VRX496, an HIV-1 based lentiviral vector for the treatment of patient-subjects infected with HIV-1; October 26th, 2001. http://www.webcitation.org/6yc5V6sUs. Accessed December 30, 2019
- Sheehy J, Zack J, Kiem HP, Handibode J. Cell/gene therapy—HIV cure research training curriculum. Located on the AVAC website (http://www.avac.org/cure-curriculum/module3), under PowerPoint. http://www.avac.org/sites/default/files/u16/Gene_Cell_Therapy_July.pptx. Accessed December 30, 2019
- Stan R and Zaia JA. Practical considerations in gene therapy for HIV cure. Curr HIVAIDS Rep. 2014;11(1):11-19.
- University of Pennsylvania. A Phase I/II, open-label, single center study to evaluate the tolerability, trafficking and therapeutic effects of repeated doses of autologous T cells transduced with VRX496 in HIV infected subjects. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). Registered on February 21, 2006. NLM Identifier: NCT00295477. https://clinicaltrials.gov/ct2/show/NCT00295477. Accessed December 30, 2019
- Tebas P, Stein D, Binder-Scholl G, et al. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood. 2013;121(9):1524-1533. doi:10.1182/blood-2012-07-447250
- Tebas P, Stein D, Zifchak L, et al. Prolonged control of viremia after transfer of autologous CD4 T cells genetically modified with a lentiviral vector expressing long antisense to HIV env (VRX496). 17th Conference on Retroviruses and Opportunistic Infections (CROI); February 16-19, 2010; San Francisco, CA. Levin: Conference Reports for National AIDS Treatment Advocacy Project (NATAP); 2010. http://www.natap.org/2010/CROI/croi_182.htm. Accessed December 30, 2019
- Rebello T, Stein D, Blick G, et al. Safety and efficacy of autologous CD4 T cells transduced with a lentiviral vector delivering anti-HIV RNA antisense env in HIV subjects failing one or more HAART regimens. Mol Ther. 2010;18:S251-S252. doi:10.1016/S1525-0016(16)38087-X
Last Reviewed: December 30, 2019